• Users Online: 98
  • Print this page
  • Email this page
ORIGINAL ARTICLE
Year : 2020  |  Volume : 4  |  Issue : 4  |  Page : 112-115

Effects of montelukast versus inhaled beclomethasone on asthma control and immunoglobulin-E levels in asthmatic children


1 Department of Pediatrics, Kerbala Teaching Hospital for Pediatrics, Kerbala, Iraq
2 Department of Pediatrics, University of Kerbala, Kerbala, Iraq
3 Department of Pharmacology, University of Kerbala, Kerbala, Iraq
4 Department of Medical Microbiology, University of Kerbala, Kerbala, Iraq

Correspondence Address:
Miss. Raghdah Maytham Hameed
Department of Medical Microbiology, University of Kerbala, Kerbala
Iraq
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/MTSM.MTSM_26_20

Rights and Permissions

Background: Beclomethasone dipropionate inhaler is a corticosteroid medication used as the controller of persistent asthma. Montelukast is a leukotriene receptor antagonist used as the second-line in controlling the symptoms of the asthmatic child. Objective: The objective of this study is to determine the comparison between the effects of beclomethasone dipropionate inhaler and montelukast on the total serum level of immunoglobulin E (IgE) and childhood asthma control test (C-ACT) in asthmatic children. Patients and Methods: A randomized clinical trial was done in Kerbala Teaching Hospital of pediatric from August 2014 to the end of October 2015, 97 patients were collected from asthma outpatient clinic aged 4 to 11 years with mild persistent asthma and randomly divided into beclomethasone group (51 patients) and montelukast group (46 patients), the total serum IgE was done before the initiation of treatment, and another reading was done after 3 months. The score of symptoms control was evaluated by C-ACT after 1 month of treatment, and another evaluation was done 2 months later. Results: There was a significant reduction in total serum IgE level (21% for montelukast group and 27% for beclomethasone group) after 3 months of treatment compared to baseline IgE, and there was significant improvement in childhood C-ACT scores (16% for montelukast group and 24% for beclomethasone group) after 3 months of treatment compared to the 1st month of treatment. There was a significant improvement in the beclomethasone group compared to the montelukast group after 3 months of treatment. Conclusions: Both beclomethasone and montelukast are effective controllers for asthma symptoms and reducing the total serum IgE level. Beclomethasone is better than montelukast in improving C-ACT scores.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed78    
    Printed6    
    Emailed0    
    PDF Downloaded14    
    Comments [Add]    

Recommend this journal